A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Who May Qualify: The main inclusion criteria include but are not limited to the following: - Is confirmed Human weakened immune system Virus (HIV)-uninfected based on negative HIV-1/HIV-2 test results - Has been sexually active (2 vaginal intercourse encounters with cisgender male individual(s) within the last 3 months) - Was assigned female sex at birth and is cisgender. - Weighs ≥35 kg Who Should NOT Join This Trial: The main exclusion criteria include but are not limited to the following: - Has hypersensitivity or other contraindication to any component of the study interventions - Has evidence of acute or chronic hepatitis B infection - Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer - Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time - Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration - Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1 Always talk to your doctor about whether this trial is right for you.